NeonMind Announces Divestiture of Consumer Related and Other Non-Core Assets Post published:September 13, 2021 Post category:Press Release
PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022 Post published:September 13, 2021 Post category:Press Release
Psychedelic Bulletin: Proliferation of Psilocybin-Related Drug Development; Biden-Harris Administration Aims to Reduce Barriers to Schedule I Research Post published:September 10, 2021 Post category:Psychedelic Bulletin
Hamilton Morris joins COMPASS Pathways to research new psychedelic compounds Post published:September 10, 2021 Post category:Press Release
MYND Life Sciences Announces Closing of Fully Subscribed $3 Million Convertible Debenture Unit Offering Post published:September 9, 2021 Post category:Press Release
Field Trip Health Ltd. to Pursue Treatment Resistant Depression and Postpartum Depression as Indications for FT-104 Post published:September 9, 2021 Post category:Press Release
Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its Novel Psilocybin-Inspired Clinical Candidate Post published:September 9, 2021 Post category:Press Release
Wesana Health Announces Closing of PsyTech Acquisition Post published:September 9, 2021 Post category:Press Release
Levitee Labs Commences Trading in U.S. Under Ticker LVTTF Post published:September 9, 2021 Post category:Press Release
atai Life Sciences and Introspect Digital Therapeutics to test novel digital therapeutic approach in patients receiving ketamine for treatment resistant depression Post published:September 9, 2021 Post category:Press Release